CDMO extends spray drying capacity for aqueous and organic solvent-based formulations
Micro-Sphere adds GEA PSD-3 spray dryer in response to increased demand in spray drying.
CDMO, Micro-Sphere has added to its decades of GMP spray drying services with the addition of new spray drying technology.
A dedicated production area houses a GEA PSD-3 spray dryer, which will extend the CDMO’s spray drying capacity for both aqueous and organic solvent-based formulations.
The new equipment is part of the CDMO’s recently announced 21 million CHF (€19 million) investment into expanding its GMP manufacturing capabilities at its facility in Switzerland and comes in response to increased demand for spray drying from companies ranging from Big Pharma to small virtual firms.
Micro-Sphere Founder and President of the Board, Dr Michele Müller, said: “Customer demand for GMP spray drying is increasing and this latest investment strengthens our production capabilities while also reaffirming our niche expertise in the market.
“The market response to our investment in our facility in Switzerland has been excellent and we are now implementing the upgrades and changes needed to offer greater capacity to handle larger quantities of pharmaceutical powders and commercial volumes of finished dosage forms.”
GEA’s technology for Spray Drying is based near Copenhagen in Denmark, where GEA develops and manufactures spray drying systems and has comprehensive test facilities for pharmaceutical customers.
Søren Terp Madsen, Product Manager at GEA added: “This new unit is equipped with the best available solutions in terms of spraying systems and cyclone for powder recovery: it offers excellent process reliability and is a great choice for Micro-Sphere in line with its continued expansion. We’re delighted to be a part of their exciting future.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.